Topical mitomycin C therapy for ocular surface neoplasia

Topical mitomycin C therapy for ocular surface neoplasia - Topical mitomycin C therapy for ocular surface neoplasia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007382

Enrollment

Registered

2012-04-30

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular surface neoplasia

Interventions

topical mitomycin C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with ocular surface neoplasia

Exclusion criteria

Exclusion criteria: patients with history of severe renal disorder, severe liver disorder or hypersensitivity to ingredients of this drug, patients with bone-marrow suppression, pregnant or lactating women and women of child-bearing potential.

Design outcomes

Primary

Measure	Time frame
tumor size, location	—

Secondary

Measure	Time frame
symptoms, best-corrected visual acuity, intraocular pressure, findings of slit-lamp examination and indirect ophthalmoscopy	—

Countries

Japan

Contacts

Public ContactTakayuki Nagai

Kobe University Hospital Department of Ophthalmology

tnagai-1@med.kobe-u.ac.jp078-382-6048

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026